Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$64.77 +1.2%	$62.83	$47.86 ▼ $107.37	$3.53B	0.28	607,479 shs	504,825 shs
MLYS Mineralys Therapeutics	$14.00 -1.7%	$14.87	$8.24 ▼ $18.38	$928.10M	-0.17	536,928 shs	511,588 shs
PTGX Protagonist Therapeutics	$55.22 +1.4%	$48.59	$31.34 ▼ $60.60	$3.37B	2.25	897,698 shs	824,720 shs
RARE Ultragenyx Pharmaceutical	$37.12 -0.8%	$36.58	$29.59 ▼ $60.37	$3.54B	0.25	830,549 shs	586,991 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	+1.16%	+1.49%	+4.55%	-4.69%	+20.70%
MLYS Mineralys Therapeutics	-1.69%	+1.97%	-11.00%	-4.50%	+26.24%
PTGX Protagonist Therapeutics	+1.43%	+2.41%	+18.93%	+12.97%	+73.87%
RARE Ultragenyx Pharmaceutical	-0.83%	-0.62%	+5.82%	-1.85%	-8.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.4764 of 5 stars	3.5	3.0	0.0	2.0	2.5	0.0
MLYS Mineralys Therapeutics	2.9203 of 5 stars	3.4	3.0	0.0	2.3	4.2	0.0
PTGX Protagonist Therapeutics	1.2362 of 5 stars	2.5	2.0	0.0	1.5	2.5	0.0
RARE Ultragenyx Pharmaceutical	4.1951 of 5 stars	3.5	3.0	3.8	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.23	71.73% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	130.36% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	19.70% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$87.00	134.38% Upside

Current Analyst Ratings Breakdown

Latest MLYS, RARE, ACLX, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/16/2025	ACLX Arcellx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/19/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$107.94M	33.07	N/A	N/A	$8.41 per share	7.70
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	7.88	$4.58 per share	12.05	$11.33 per share	4.87
RARE Ultragenyx Pharmaceutical	$560.23M	6.26	N/A	N/A	$2.76 per share	13.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	73.63	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)

Latest MLYS, RARE, ACLX, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.93	4.93
MLYS Mineralys Therapeutics	N/A	26.48	26.48
PTGX Protagonist Therapeutics	N/A	17.25	17.26
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
MLYS Mineralys Therapeutics	84.46%
PTGX Protagonist Therapeutics	98.63%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
MLYS Mineralys Therapeutics	25.56%
PTGX Protagonist Therapeutics	4.90%
RARE Ultragenyx Pharmaceutical	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable

MLYS, RARE, ACLX, and PTGX Headlines

Recent News About These Companies

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

1 hour ago | globenewswire.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 2,405 Shares

June 24 at 4:52 AM | insidertrades.com

FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent

June 23, 2025 | biospace.comB

Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells 2,405 Shares of Stock

June 23, 2025 | marketbeat.com

Guggenheim Reiterates "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)

June 22, 2025 | americanbankingnews.com

Ultragenyx Pharmaceutical Inc. Grants 48,731 Restricted Stock Units to Newly Hired Non-Executive Officers

June 20, 2025 | quiverquant.comQ

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2025 | globenewswire.com

Guggenheim Reaffirms Buy Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)

June 20, 2025 | marketbeat.com

GAMMA Investing LLC Acquires 26,625 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 17, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Assenagon Asset Management S.A.

June 15, 2025 | marketbeat.com

Wealth Enhancement Advisory Services LLC Sells 14,701 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 15, 2025 | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 3.5% - What's Next?

June 12, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by SG Americas Securities LLC

June 12, 2025 | marketbeat.com

Wedge Capital Management L L P NC Buys Shares of 35,695 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 11, 2025 | marketbeat.com

Research Analysts Offer Predictions for RARE FY2026 Earnings

June 10, 2025 | marketbeat.com

China's rare earth exports climb 23% in May ahead of trade talks with the U.S.

June 9, 2025 | msn.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Brokerages

June 8, 2025 | marketbeat.com

Ultragenyx Pharmaceutical reports Q1 earnings

June 6, 2025 | pressdemocrat.comP

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

June 5, 2025 | zacks.com

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | globenewswire.com

Mackenzie Financial Corp Acquires 11,825 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
Why Qualcomm’s Latest Price Target Can't Be Ignored
By Sam Quirke | June 24, 2025
View Why Qualcomm’s Latest Price Target Can't Be Ignored
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
By Sam Quirke | June 11, 2025
View Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal

MLYS, RARE, ACLX, and PTGX Company Descriptions

Arcellx NASDAQ:ACLX

$64.77 +0.74 (+1.16%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$64.77 0.00 (0.00%)

As of 06/26/2025 06:18 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Mineralys Therapeutics NASDAQ:MLYS

$14.00 -0.24 (-1.69%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$14.03 +0.03 (+0.21%)

As of 06/26/2025 04:23 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Protagonist Therapeutics NASDAQ:PTGX

$55.22 +0.78 (+1.43%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$55.31 +0.09 (+0.16%)

As of 04:11 AM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$37.12 -0.31 (-0.83%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$39.03 +1.91 (+5.15%)

As of 08:22 AM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time